The U.S. Supreme Court sided with Hikma Pharmaceuticals in a unanimous decision involving its ‘skinny label’ generic version of Amarin’s Vascepa. The ruling held that Hikma’s product did not infringe the patents at issue, reversing a lower-court decision. The decision strengthens the legal pathway for generics marketed for specific indications without infringing patents on other uses, shaping how label language and marketing conduct are treated in patent-inducement disputes. For biotech and pharma, the ruling is a direct commercial headwind for brand owners with remaining indication-specific patent fences, while reinforcing predictable entry mechanics for generic challengers.